NANO (NANO) News
Follow NANO (NANO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: H1 2026 finances and NSCLC Phase 1 79% 1—yr control, 33% GTV
Nanobiotix SA ADR (NASDAQ:NBTX) reported H1 2026 revenue plunged to €5.6M and a €34.3M net loss while cash of €110.9M funds operations into 2029, even as UT MD Anderson Phase 1 data for JNJ—1900 (NBTXR3) in NSCLC showed
NEWS | Sep 28, 2026, 11:06 AM UTC
L
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feed
EARNINGS | Sep 24, 2026, 08:24 PM UTC
L
Nanobiotix (NANO) Posts €34.3M H1 Loss; Cash €110.9M, Runway Into 2029
Nanobiotix reported H1 2026 net loss of €34.3M vs €5.4M a year ago, revenue and other income of €5.6M vs €26.6M, and cash of €110.9M at June 30. The company guides its cash runway into 2029.Material DetailsContext by AI
EARNINGS | Sep 24, 2026, 08:21 PM UTC
L
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treat
NEWS | Sep 24, 2026, 08:21 PM UTC
L
Nanobiotix Expects Cash and Cash Equivalents Will Fund Its Ops Into 2029 >NANO.FR
Nanobiotix Expects Cash and Cash Equivalents Will Fund Its Ops Into 2029 >NANO.FR
NEWS | Sep 24, 2026, 08:19 PM UTC
L
Nanobiotix Had EUR110.9 M in Cash and Cash Equivalents as of June 30 >NANO.FR
Nanobiotix Had EUR110.9 M in Cash and Cash Equivalents as of June 30 >NANO.FR
NEWS | Sep 24, 2026, 08:18 PM UTC
L
Nanobiotix 1H Basic Loss/Shr EUR0.70 >NANO.FR
Nanobiotix 1H Basic Loss/Shr EUR0.70 >NANO.FR
NEWS | Sep 24, 2026, 08:18 PM UTC
L
Nanobiotix 1H Revenue and Other Income EUR5.6 M >NANO.FR
Nanobiotix 1H Revenue and Other Income EUR5.6 M >NANO.FR
NEWS | Sep 24, 2026, 08:18 PM UTC
L
Nanobiotix Coverage Assumed by Guggenheim at Buy
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:27 PM UTC
L
Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Nanobiotix SA EURONEXT:NANO
NEWS | Sep 14, 2026, 06:11 AM UTC
L
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
Data presented at the IASLC 2026 World Conference on Lung CancerPARIS and CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnolo
NEWS | Sep 14, 2026, 06:01 AM UTC
L
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatme
EQUITY | Sep 09, 2026, 08:21 PM UTC
L
Nano One appoints Aleem Ladak as Director of Corporate Development
Nano One Appoints Aleem Ladak as Director of Corporate Development.
EQUITY | Sep 01, 2026, 07:05 AM UTC
L
Nano One advances global LFP cathode strategy
Nano One said it is advancing its global LFP cathode strategy as demand from energy storage, EV and defence applications accelerates.
EQUITY | Aug 26, 2026, 07:05 AM UTC